Adaptive Biotechnologies (ADPT) Accounts Payables (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Accounts Payables data on file, last reported at $9.6 million in Q1 2026.

• Quarterly Accounts Payables rose 51.13% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (up 51.13% YoY) and the FY2025 annual result came in at $6.5 million, down 10.98% from the prior year.
• Accounts Payables climbed to $9.6 million in Q1 2026 per ADPT's latest filing, from $6.5 million in the prior quarter.
• The five-year high for Accounts Payables was $12.2 million in Q1 2024, with the low at $2.7 million in Q2 2022.
• Average Accounts Payables over 5 years is $7.3 million, with a median of $7.3 million recorded in 2024.
• Year-over-year, Accounts Payables sank 55.36% in 2022 and soared 236.88% in 2023.
• Adaptive Biotechnologies' Accounts Payables stood at $8.1 million in 2022, then retreated by 4.52% to $7.7 million in 2023, then decreased by 5.88% to $7.3 million in 2024, then retreated by 10.98% to $6.5 million in 2025, then surged by 48.68% to $9.6 million in 2026.
• Business Quant data shows ADPT's Accounts Payables at $9.6 million in Q1 2026, $6.5 million in Q4 2025, and $10.3 million in Q3 2025.